> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Panel to Review to NDAs in May
- URL: https://www.fdaweb.com/oncologic-panel-to-review-to-ndas-in-may/
- Published: 2017-04-19T12:00:00.000Z
- Updated: 2026-09-14T22:18:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138489

*Federal Register* notice: FDA has announced a 5/24 Oncologic Drugs Advisory Committee meeting that will review two NDAs. In the morning session, panel members will discuss a Puma Biotechnology NDA for neratinib maleate, indicated as a single agent for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant traustuzumab-based therapy. During the afternoon session, the committee will discuss an Emmaus Medical NDA for L-glutamine powder (oral solution), indicated for treating sickle cell disease. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-04-18/pdf/2017-07771.pdf?ref=fdaweb.com).